111 results on '"A Terragna"'
Search Results
2. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
3. Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma
4. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment
5. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
6. The Use of Next Generation Flow in Multiple Myeloma Patients: A Preliminary Real-Life Multicenter MRD Harmonization Experience
7. P-383 A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies
8. P-370 CoMMsol: a machine learning model for outcome-specific copy number alterations' clonality cut-offs definition in multiple myeloma
9. P-068 Implementation of next generation sequencing as best tool for routine evaluation of minimal residual disease in the daily practice of multiple myeloma patients
10. OA-22 TiMMing: developing an innovative suite of bioinformatic tools to harmonize and track the origin of copy number alterations in the evolutionary history of multiple myeloma
11. Positive Selection and Transplantation of Autologous Highly Purified CD133 + Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging
12. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
13. A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies
14. P-077: Multiple myeloma genomic landscape explored by dimensional scaling technique highlights the presence of 1q&13+ patients with specific genomic, transcriptional and clinical features
15. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation
16. Human CD34 + blood cells induce T-cell unresponsiveness to specific alloantigens only under costimulatory blockade
17. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state
18. Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage
19. High Humoral Response after Anti-Sars-Cov-2 mRNA-Based Vaccines in Patients with Active Multiple Myeloma (MM) and Relationship with Disease Status/Line of Therapy
20. P-053: BoBafit: a Copy Number-clustering tool to refit and recalibrate the diploid region of Multiple Myeloma genomic profiles
21. P-036: Implementation of IgH/k Next Generation Sequencing for Multiple Myeloma Minimal Residual Disease monitoring: advantages in patients’ management during daily clinical practice.
22. OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival
23. OAB-059: Towards a comprehensive multimodal minimal residual disease assessment in multiple myeloma: the role of circulating cell-free DNA to define the extent of disease spreading
24. OAB-041: Epithelial-mesenchymal-transition regulated by Junctional Adhesion Molecule-A (JAM-A) associates with aggressive extramedullary multiple myeloma disease
25. OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma
26. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma
27. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy
28. High-Risk Multiple Myeloma Patients Are Missed without Gene Expression Profiling
29. ALL-073: Inotuzumab Ozogamicin (IO) and Donor Lymphocyte Infusion (DLI) are a Safe and Promising Combination in Relapsed Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
30. The Treatment of Hairy Cell Leukemia with a Focus on Long Lasting Responders to Cladribine: A Thirty-Year Experience from the Institute of Hematology of Bologna
31. Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival
32. Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients
33. The Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma
34. Serum Free Light Chain Assay As an Additional Tool for Defining Response and Progressive Disease in Immunoglobulin Secretory Multiple Myeloma
35. A Maturation Index Defines Newly Diagnosed Multiple Myeloma Patients with Advanced Immunophenotypic and Molecular Differentiation Profiles Associated with Poor Prognosis
36. Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma
37. Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients
38. VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma
39. A Maturation Index defines Newly Diagnosed Multiple Myeloma Patients with advanced immunophenotypic and Molecular Differentiation profiles associated with poor prognosis
40. Analysis of the genomic and transcriptomic landscape of chemoresistant multiple myeloma
41. Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes
42. Age, Disease Status before Blinatumomab, MRD Negativity Obtainment, and Bridge to Transplant Influence Outcome in Patients with B-ALL: A Single Center Experience
43. Mmprofiler with SKY92 Combined with ISS Identifies High and Low Risk Multiple Myeloma in the VTD Arm of Gimema-MMY-3006
44. Definition of a Prognostic Risk-Classifier Based on SNPs Array Analysis of Copy Number Alterations in Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients
45. The Pliancy of Plasma Cell Differentiation Status Conceals a Gradient of Chromosomal Instability in Newly Diagnosed Multiple Myeloma Patients
46. High-Risk Cytogenetics in Newly Diagnosed Multiple Myeloma: Prognostic Relevance of Co-Segregations and Analysis of the Role of Double Versus Single Autotransplantation
47. First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
48. Evolutionary Fitness of Relapsed Multiple Myeloma Patients Who Responded to Upfront Combination Therapy Including New Drugs
49. A More Mature Immunophenotypic Make-up of Multiple Myeloma Clone(s) at Diagnosis Correlates With a Higher Genomic Instability
50. Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.